Cargando…

The Inflammatory and Hemostatic Cardiovascular Risk Markers During Acute Hyperglycemic Crisis in Type 1 and Type 2 Diabetes

BACKGROUND: We analyzed cardiovascular inflammatory (C-reactive protein (CRP), interleukin 6 (IL-6)), haemostatic (homocysteine) risk markers in lean and obese patients at admission and acute hyperglicemic crisis (AHC) resolving, involving diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic s...

Descripción completa

Detalles Bibliográficos
Autores principales: Popovic, Dragana, Lalic, Katarina, Jotic, Aleksandra, Milicic, Tanja, Bogdanovic, Jelena, Đorđevic, Maja, Stankovic, Sanja, Jeremic, Veljko, Lalic, Nebojsa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410996/
https://www.ncbi.nlm.nih.gov/pubmed/30867640
http://dx.doi.org/10.2478/jomb-2018-0024
_version_ 1783402327810506752
author Popovic, Dragana
Lalic, Katarina
Jotic, Aleksandra
Milicic, Tanja
Bogdanovic, Jelena
Đorđevic, Maja
Stankovic, Sanja
Jeremic, Veljko
Lalic, Nebojsa M.
author_facet Popovic, Dragana
Lalic, Katarina
Jotic, Aleksandra
Milicic, Tanja
Bogdanovic, Jelena
Đorđevic, Maja
Stankovic, Sanja
Jeremic, Veljko
Lalic, Nebojsa M.
author_sort Popovic, Dragana
collection PubMed
description BACKGROUND: We analyzed cardiovascular inflammatory (C-reactive protein (CRP), interleukin 6 (IL-6)), haemostatic (homocysteine) risk markers in lean and obese patients at admission and acute hyperglicemic crisis (AHC) resolving, involving diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS). METHODS: In that context, we included group A: N = 20 obese, B: N=20 lean patients with DKA; C: N = l0 obese, D: N=10 lean patients with HHS; E: N = 15 obese, F: N=15 lean controls. CRP IL-6, homocysteine were determined by ELISA. RESULTS: Our results showed that CRP IL-6, and homocysteine levels decreased in all groups: (A: p<0.001; B: p<0.001, C: p<0.05; D: p<0.001 mg/L), (A: p<0.001 B: p<0.001, C: p<0.001, D: p<0.01 pg/mL), (A: p<0.001, B: p <0.001; C: p<0.05, D: p=0.001 μmol/L), respectively, at resolving AHC. However, CRP persisted higher (p<0.001, p<0.01), IL-6 lower (p<0.05, p<0.001), while homocysteine levels turned out to be similar to controls. CONCLUSIONS: AHC is associated with increased inflammatory and hemostatic cardiovascular risk markers. Also, insulin therapy in AHC has had more pronounced favorable effect on IL-6 and homocystein than on CRP
format Online
Article
Text
id pubmed-6410996
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Sciendo
record_format MEDLINE/PubMed
spelling pubmed-64109962019-03-13 The Inflammatory and Hemostatic Cardiovascular Risk Markers During Acute Hyperglycemic Crisis in Type 1 and Type 2 Diabetes Popovic, Dragana Lalic, Katarina Jotic, Aleksandra Milicic, Tanja Bogdanovic, Jelena Đorđevic, Maja Stankovic, Sanja Jeremic, Veljko Lalic, Nebojsa M. J Med Biochem Original Paper BACKGROUND: We analyzed cardiovascular inflammatory (C-reactive protein (CRP), interleukin 6 (IL-6)), haemostatic (homocysteine) risk markers in lean and obese patients at admission and acute hyperglicemic crisis (AHC) resolving, involving diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS). METHODS: In that context, we included group A: N = 20 obese, B: N=20 lean patients with DKA; C: N = l0 obese, D: N=10 lean patients with HHS; E: N = 15 obese, F: N=15 lean controls. CRP IL-6, homocysteine were determined by ELISA. RESULTS: Our results showed that CRP IL-6, and homocysteine levels decreased in all groups: (A: p<0.001; B: p<0.001, C: p<0.05; D: p<0.001 mg/L), (A: p<0.001 B: p<0.001, C: p<0.001, D: p<0.01 pg/mL), (A: p<0.001, B: p <0.001; C: p<0.05, D: p=0.001 μmol/L), respectively, at resolving AHC. However, CRP persisted higher (p<0.001, p<0.01), IL-6 lower (p<0.05, p<0.001), while homocysteine levels turned out to be similar to controls. CONCLUSIONS: AHC is associated with increased inflammatory and hemostatic cardiovascular risk markers. Also, insulin therapy in AHC has had more pronounced favorable effect on IL-6 and homocystein than on CRP Sciendo 2019-03-03 /pmc/articles/PMC6410996/ /pubmed/30867640 http://dx.doi.org/10.2478/jomb-2018-0024 Text en © 2019 Dragana Popovic, Katarina Lalic, Aleksandra Jotic, Tanja Milicic, Jelena Bogdanovic, Maja Đorđevic, Sanja Stankovic, Veljko Jeremic, Nebojsa M. Lalic, published by Sciendo http://creativecommons.org/licenses/by-nc-nd/3.0 This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
spellingShingle Original Paper
Popovic, Dragana
Lalic, Katarina
Jotic, Aleksandra
Milicic, Tanja
Bogdanovic, Jelena
Đorđevic, Maja
Stankovic, Sanja
Jeremic, Veljko
Lalic, Nebojsa M.
The Inflammatory and Hemostatic Cardiovascular Risk Markers During Acute Hyperglycemic Crisis in Type 1 and Type 2 Diabetes
title The Inflammatory and Hemostatic Cardiovascular Risk Markers During Acute Hyperglycemic Crisis in Type 1 and Type 2 Diabetes
title_full The Inflammatory and Hemostatic Cardiovascular Risk Markers During Acute Hyperglycemic Crisis in Type 1 and Type 2 Diabetes
title_fullStr The Inflammatory and Hemostatic Cardiovascular Risk Markers During Acute Hyperglycemic Crisis in Type 1 and Type 2 Diabetes
title_full_unstemmed The Inflammatory and Hemostatic Cardiovascular Risk Markers During Acute Hyperglycemic Crisis in Type 1 and Type 2 Diabetes
title_short The Inflammatory and Hemostatic Cardiovascular Risk Markers During Acute Hyperglycemic Crisis in Type 1 and Type 2 Diabetes
title_sort inflammatory and hemostatic cardiovascular risk markers during acute hyperglycemic crisis in type 1 and type 2 diabetes
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410996/
https://www.ncbi.nlm.nih.gov/pubmed/30867640
http://dx.doi.org/10.2478/jomb-2018-0024
work_keys_str_mv AT popovicdragana theinflammatoryandhemostaticcardiovascularriskmarkersduringacutehyperglycemiccrisisintype1andtype2diabetes
AT lalickatarina theinflammatoryandhemostaticcardiovascularriskmarkersduringacutehyperglycemiccrisisintype1andtype2diabetes
AT joticaleksandra theinflammatoryandhemostaticcardiovascularriskmarkersduringacutehyperglycemiccrisisintype1andtype2diabetes
AT milicictanja theinflammatoryandhemostaticcardiovascularriskmarkersduringacutehyperglycemiccrisisintype1andtype2diabetes
AT bogdanovicjelena theinflammatoryandhemostaticcardiovascularriskmarkersduringacutehyperglycemiccrisisintype1andtype2diabetes
AT đorđevicmaja theinflammatoryandhemostaticcardiovascularriskmarkersduringacutehyperglycemiccrisisintype1andtype2diabetes
AT stankovicsanja theinflammatoryandhemostaticcardiovascularriskmarkersduringacutehyperglycemiccrisisintype1andtype2diabetes
AT jeremicveljko theinflammatoryandhemostaticcardiovascularriskmarkersduringacutehyperglycemiccrisisintype1andtype2diabetes
AT lalicnebojsam theinflammatoryandhemostaticcardiovascularriskmarkersduringacutehyperglycemiccrisisintype1andtype2diabetes
AT popovicdragana inflammatoryandhemostaticcardiovascularriskmarkersduringacutehyperglycemiccrisisintype1andtype2diabetes
AT lalickatarina inflammatoryandhemostaticcardiovascularriskmarkersduringacutehyperglycemiccrisisintype1andtype2diabetes
AT joticaleksandra inflammatoryandhemostaticcardiovascularriskmarkersduringacutehyperglycemiccrisisintype1andtype2diabetes
AT milicictanja inflammatoryandhemostaticcardiovascularriskmarkersduringacutehyperglycemiccrisisintype1andtype2diabetes
AT bogdanovicjelena inflammatoryandhemostaticcardiovascularriskmarkersduringacutehyperglycemiccrisisintype1andtype2diabetes
AT đorđevicmaja inflammatoryandhemostaticcardiovascularriskmarkersduringacutehyperglycemiccrisisintype1andtype2diabetes
AT stankovicsanja inflammatoryandhemostaticcardiovascularriskmarkersduringacutehyperglycemiccrisisintype1andtype2diabetes
AT jeremicveljko inflammatoryandhemostaticcardiovascularriskmarkersduringacutehyperglycemiccrisisintype1andtype2diabetes
AT lalicnebojsam inflammatoryandhemostaticcardiovascularriskmarkersduringacutehyperglycemiccrisisintype1andtype2diabetes